jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vakcinos - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.
vidprevtyn beta
sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vakcinos - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ir 5. 1 in product information document). naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcinos - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.
rely+on™ virkon™.
lanxess deutschland gmbh, kennedyplatz 1, de-50569 cologne (vokietija). - pentakalio bis(peroksimonosulfato)bis(sulfatas) - veikliosios medžiagos cas nr.: 70693-62-8, eb nr.: 274-778-7, veikliosios medžiagos pavadinimas: pentakalio bis(peroksimonosulfato)bis(sulfatas), koncentracija: 49.7% , veiklioji - dezinfekantai ir algicidai, kurie nėra skirti tiesioginiam žmonių ar gyvūnų naudojimui